Scabies In Dogs: Comprehensive Veterinary Reference Guide

Quick Q&A

Question: Can humans catch scabies from dogs? Answer: Yes, scabies in dogs is zoonotic. The mite Sarcoptes scabiei var. canis can transiently infest humans, causing intense itching and a papular rash, typically on the arms, trunk, and abdomen. However, the mites cannot complete their life cycle on human skin and usually die within a few days, leading to self-resolution once the dog is treated.

Introduction

Scabies, also known as sarcoptic mange, is a highly contagious, pruritic skin disease of dogs caused by the ectoparasitic mite Sarcoptes scabiei var. canis. This condition represents one of the most common differential diagnoses for intense pruritus in canine practice and carries significant zoonotic potential, making it a disease of both veterinary and public health importance. The global distribution of scabies is well documented, with prevalence rates varying by geographic region, management practices, and host population density [13, 22].

The clinical hallmark of scabies in dogs is severe, often debilitating pruritus that typically precedes the development of visible skin lesions. The disease can affect dogs of any age, breed, or sex, though young animals and those with compromised immune systems may exhibit more severe clinical signs. The economic and welfare impacts are substantial, as affected dogs suffer from chronic discomfort, secondary bacterial infections, and, in severe cases, systemic illness including weight loss and debilitation.

This comprehensive veterinary reference guide provides an exhaustive review of scabies in dogs, covering etiology, epidemiology, pathophysiology, clinical presentation, diagnostic approaches, treatment modalities, prevention strategies, and zoonotic considerations. The content synthesizes current peer-reviewed literature, international clinical guidelines, and expert consensus to deliver a publication-grade resource for veterinary professionals and informed pet owners.

Etiology and Life Cycle

The Causative Agent

Scabies in dogs is caused by the astigmatid mite Sarcoptes scabiei var. canis, a member of the family Sarcoptidae. The mite is an obligate, burrowing parasite that completes its entire life cycle on the host. Adult mites are round, ventrally flattened, and approximately 300-500 micrometers in length, making them visible under low-power microscopy. They possess four pairs of short, stubby legs; the anterior two pairs bear suckers (pulvilli) on long unjointed stalks, while the posterior pairs in females end in long bristles (setae) [20].

Recent comparative genomic studies have provided new insights into the adaptation of S. scabiei to permanent parasitism. Analysis of the mite genome reveals extensive gene family expansions related to digestion, detoxification, and host immune evasion, as well as the loss of genes required for free-living existence [25]. These adaptations underscore the mite's complete dependence on the host and explain the difficulty in eradicating infestations without effective acaricidal therapy.

Life Cycle

The life cycle of Sarcoptes scabiei consists of five stages: egg, larva, protonymph, tritonymph, and adult. The entire cycle from egg to egg takes approximately 17-21 days under optimal conditions on the canine host.

1. Egg Stage: The female mite burrows into the stratum corneum of the epidermis, creating a serpentine tunnel where she deposits 2-3 eggs per day over her lifespan of 4-6 weeks. Eggs are oval, approximately 150-200 micrometers in length, and are cemented to the tunnel floor.

2. Larval Stage: After 3-5 days, six-legged larvae hatch from the eggs. Larvae may remain within the maternal burrow or emerge onto the skin surface to create new shallow burrows or invade hair follicles.

3. Nymphal Stages: The larva molts into a protonymph (8 legs) and then a tritonymph (8 legs). Each nymphal stage lasts 3-4 days, during which the mites feed on epidermal cells and tissue fluid.

4. Adult Stage: After the final molt, adult males emerge and actively seek females on the skin surface. Mating occurs on the skin or in shallow burrows. After mating, the male dies, and the gravid female burrows into the stratum corneum to begin oviposition.

The rapid life cycle and high fecundity of female mites explain the exponential increase in mite populations on untreated hosts. A single infested dog may harbor thousands to millions of mites, depending on the duration and severity of infestation.

Epidemiology and Transmission

Global Distribution

Scabies in dogs has a worldwide distribution, with prevalence rates influenced by geographic location, climate, host population density, and management practices. In a study of stray dogs in Bursa Province, Turkey, the prevalence of sarcoptic mange was reported at 12.3%, highlighting the significance of this disease in free-roaming canine populations [13]. Similarly, epidemiological surveys in Brazil have documented high prevalence rates in regions with large stray dog populations and limited veterinary access [9].

Wildlife reservoirs play a crucial role in the epidemiology of scabies. Red foxes (Vulpes vulpes), gray foxes (Urocyon cinereoargenteus), and other canid species are important sylvatic reservoirs that can maintain mite populations and serve as sources of infestation for domestic dogs. A study of sarcoptic mange in wild foxes from central Chile demonstrated that the disease is endemic in these populations, with prevalence rates varying seasonally and spatially [6, 14]. The epidemiology of sarcoptic mange in geographically constrained insular red fox populations further illustrates how landscape features and host density influence disease dynamics [8].

Transmission Routes

Direct contact with an infested host is the primary mode of transmission for S. scabiei. The mites are highly host-adapted but can survive off the host for limited periods, typically 2-4 days under cool, humid conditions. This environmental survival allows for indirect transmission via contaminated bedding, grooming tools, kennel surfaces, and other fomites.

Transmission dynamics are influenced by several factors:

• Host Density: Higher population densities facilitate more rapid spread. Kennels, shelters, and multi-dog households are at increased risk.
• Host Behavior: Social behaviors such as communal sleeping, grooming, and play facilitate direct contact transmission.
• Environmental Conditions: Cool, humid environments prolong mite survival off the host, increasing the risk of indirect transmission.
• Immune Status: Immunocompromised animals may harbor higher mite burdens and shed more mites into the environment.

Risk Factors

Young dogs, particularly those under 2 years of age, are at increased risk for scabies. This age predisposition may reflect naive immune systems and increased social interactions. Dogs with pre-existing dermatological conditions, poor nutrition, or concurrent systemic diseases are also more susceptible to severe infestations.

Stray and free-roaming dogs represent a high-risk population. Studies of stray dogs consistently report higher prevalence rates compared to owned dogs, reflecting increased exposure to infested conspecifics and wildlife reservoirs [13]. In regions with large stray dog populations, the risk of spillover to owned dogs is elevated, particularly in areas where dogs are allowed to roam freely.

Pathophysiology and Immune Response

Burrowing and Tissue Damage

The pathological changes associated with scabies in dogs result from both direct mite activity and the host immune response. Female mites create burrows within the stratum corneum, mechanically disrupting the epidermal barrier. The burrowing activity, combined with the secretion of salivary enzymes and fecal material, triggers an inflammatory cascade.

Mite saliva contains proteolytic enzymes, including cysteine and serine proteases, that facilitate tissue penetration and digestion. These enzymes also act as potent allergens, stimulating both immediate (Type I) and delayed (Type IV) hypersensitivity reactions. The host immune response to mite antigens is the primary driver of the intense pruritus characteristic of scabies.

Immunological Mechanisms

The immune response to S. scabiei is complex and involves both innate and adaptive components. Early infestation is characterized by a predominantly Th1 response, with production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha). As infestation progresses, a Th2 response develops, characterized by interleukin-4 (IL-4), IL-5, and IL-13 production, leading to eosinophilia and IgE-mediated hypersensitivity.

A systematic review and meta-analysis of immunological changes associated with S. scabiei infection documented significant alterations in circulating leukocyte populations, acute-phase proteins, and cytokine profiles [26]. Dogs with sarcoptic mange exhibit elevated serum concentrations of C-reactive protein, haptoglobin, and serum amyloid A, with the magnitude of elevation correlating with clinical severity [27].

The development of protective immunity is variable. Some dogs develop resistance to reinfestation following successful treatment, while others remain susceptible. This variability likely reflects differences in the quality and magnitude of the immune response, as well as potential immune evasion strategies employed by the mite.

Secondary Complications

Chronic scabies infestations frequently lead to secondary complications:

• Pyoderma: The intense pruritus and self-trauma associated with scabies disrupt the epidermal barrier, predisposing to secondary bacterial infections. Staphylococcus pseudintermedius is the most common isolate. The presence of concurrent pyoderma can complicate diagnosis and treatment, as the clinical signs of pyoderma may overlap with or mask those of scabies [27].

• Peripheral Lymphadenopathy: Regional lymph node enlargement is common in chronic cases, reflecting the robust immune response to mite antigens.

• Systemic Effects: Severe, untreated infestations can lead to weight loss, hypoproteinemia, and debilitation. In extreme cases, particularly in young or immunocompromised animals, scabies can be fatal.

Clinical Presentation

Classic Signs

The clinical presentation of scabies in dogs is characterized by intense, often paroxysmal pruritus that is typically more severe than the visible skin lesions would suggest. The pruritus is frequently exacerbated by warmth and may be more noticeable at night.

Primary Lesions: The earliest visible lesions are erythematous papules and small crusts, often located at the sites of mite burrowing. The classic "scabies papule" is a small, erythematous, excoriated papule that may have a central crust. Burrows, though pathognomonic, are often difficult to visualize in dogs due to the presence of hair and self-trauma.

Distribution Pattern: The distribution of lesions in canine scabies follows a characteristic pattern:

• Pinnae: The margins of the pinnae are frequently affected, with erythema, crusting, and alopecia. The "pinnal-pedal reflex" (scratching of the hindlimb when the pinnal margin is rubbed) is a classic, though not pathognomonic, finding.
• Elbows and Hocks: The lateral aspects of the elbows and the point of the hocks are commonly affected, with alopecia, lichenification, and hyperpigmentation in chronic cases.
• Ventral Abdomen and Chest: The ventral abdomen, axillae, and inguinal region often exhibit erythema, papules, and excoriations.
• Face and Periocular Region: Facial involvement is common, with periocular alopecia and crusting.

Secondary Lesions: Chronic self-trauma leads to alopecia, excoriations, lichenification, hyperpigmentation, and scaling. In severe cases, the skin may become thickened and folded, particularly in the axillae and inguinal region.

Clinical Variants

Scabies in Puppies: Young dogs often present with more severe clinical signs, including generalized alopecia, marked crusting, and systemic signs such as lethargy and poor growth. The distribution may be more diffuse, with less distinction between affected and unaffected areas.

Scabies in Immunocompromised Dogs: Dogs with concurrent immunosuppressive conditions (e.g., hyperadrenocorticism, leishmaniasis, chemotherapy) may develop Norwegian or crusted scabies, characterized by thick, hyperkeratotic crusts and high mite burdens. This form is highly contagious and associated with more severe zoonotic risk.

Subclinical Infestations: Some dogs, particularly those with prior exposure, may harbor low numbers of mites without exhibiting clinical signs. These subclinically infested animals can serve as reservoirs for infestation of other animals and humans.

Differential Diagnoses

The differential diagnosis for pruritic skin disease in dogs is broad, and scabies must be distinguished from other causes of intense pruritus:

• Atopic Dermatitis: Atopic dogs typically present with pruritus affecting the face, ears, paws, and ventral abdomen. Recent research has identified PDE4D and miR-203 as promising biomarkers for canine atopic dermatitis, which may aid in differentiation [10]. However, atopic dermatitis is a diagnosis of exclusion, and scabies should be ruled out before making this diagnosis.

• Food Allergy: Food-allergic dogs may present with pruritus that is non-seasonal and may affect the ears, paws, and perianal region. Dietary elimination trials are required for definitive diagnosis.

• Flea Allergy Dermatitis: Flea-allergic dogs typically exhibit pruritus affecting the dorsal lumbosacral region, tail head, and caudal thighs. The presence of fleas or flea dirt supports this diagnosis.

• Demodicosis: Demodicosis, caused by Demodex canis or Demodex injai, typically presents with alopecia, erythema, and scaling. Pruritus is variable and often less severe than in scabies. Deep skin scrapings are diagnostic.

• Dermatophytosis: Fungal infections caused by Microsporum canis or Trichophyton mentagrophytes may present with circular areas of alopecia, scaling, and crusting. Pruritus is variable. Fungal culture or PCR is diagnostic.

• Pyoderma: Primary bacterial skin infections may present with papules, pustules, and crusts. Pruritus is common but typically less intense than in scabies. Cytology and response to antibiotics aid in diagnosis.

• Cutaneous Adverse Drug Reaction: Drug eruptions can mimic many dermatoses. A thorough history of recent medication administration is essential.

Diagnostic Approach

History and Signalment

A thorough history is essential for guiding the diagnostic workup. Key historical points include:

• Onset and duration of pruritus
• Progression of lesions
• Response to previous treatments (particularly corticosteroids)
• Contact with other dogs, wildlife, or potentially contaminated environments
• Presence of pruritus in other animals or human household members

The signalment may provide clues, as young dogs and certain breeds (e.g., those predisposed to atopic dermatitis) are overrepresented.

Physical Examination

A complete physical examination should be performed, with particular attention to the distribution of skin lesions. The "pinnal-pedal reflex" should be assessed by rubbing the margin of the pinna between the thumb and forefinger. A positive reflex (scratching of the hindlimb) is supportive of scabies but is not pathognomonic.

Skin Scrapings

Deep skin scrapings remain the standard diagnostic test for scabies in dogs. The technique involves:

1. Selecting a fresh, non-excoriated papule or crust (often on the pinnal margin or elbow).
2. Applying a drop of mineral oil to the lesion and the scalpel blade.
3. Scraping the lesion with a #10 or #15 scalpel blade held at a 90-degree angle to the skin until capillary bleeding is observed.
4. Transferring the collected material to a glass slide, adding a coverslip, and examining under 4x and 10x magnification.

The sensitivity of skin scrapings is variable, reported at 20-50% in many studies. Multiple scrapings from different sites increase diagnostic yield. A modified centrifugation-flotation technique using sucrose solution has been shown to improve mite recovery compared to standard scraping alone [31].

Dermoscopy

Dermoscopy (also called epiluminescence microscopy or entodermoscopy) is a non-invasive diagnostic tool that has gained popularity in veterinary dermatology. The technique involves applying immersion oil or alcohol to the skin and examining the area with a handheld dermoscope at 10x magnification.

The characteristic dermoscopic finding in scabies is the "mite-gallery unit," which appears as a small, dark, triangular structure (the mite's anterior end) at the end of a serpiginous burrow [5]. Dermoscopy has been reported to have higher sensitivity than skin scrapings in some studies, particularly when examining the pinnal margins and interdigital spaces [29].

Molecular Diagnostics

PCR-based assays for detection of S. scabiei DNA in skin scrapings, skin biopsies, and even tape strip samples have been developed. These assays target specific genetic markers, including the cox1 gene and internal transcribed spacer (ITS) regions. Molecular detection offers higher sensitivity than microscopy and can confirm the diagnosis even when mite counts are low [32].

Recent advances include the development of rapid immunodiagnostic assays based on transcriptomic analysis of S. scabiei antigens. These point-of-care tests have shown promise for field use and in resource-limited settings [33].

Serology

Serological assays for detection of anti-Sarcoptes antibodies are available in some reference laboratories. These tests detect IgG antibodies against mite antigens and can be useful for confirming exposure in cases where skin scrapings are negative. However, serology cannot distinguish between active infestation and prior exposure, and cross-reactivity with other mite species has been reported.

Therapeutic Trial

In cases where diagnostic testing is inconclusive but clinical suspicion remains high, a therapeutic trial with an acaricidal agent is warranted. A positive response to treatment (resolution of pruritus and skin lesions within 2-4 weeks) supports the diagnosis of scabies. This approach is particularly useful in practice settings where access to advanced diagnostics is limited.

Histopathology

Skin biopsy is not routinely recommended for diagnosis of scabies but may be helpful in atypical or chronic cases. Histopathological findings include superficial perivascular dermatitis with eosinophils, spongiosis, and, occasionally, mites or mite fragments within the stratum corneum. The sensitivity of biopsy for detecting mites is low, and multiple sections may need to be examined.

Treatment

Principles of Treatment

Successful treatment of scabies in dogs requires:

1. Elimination of mites from the affected animal
2. Treatment of all in-contact animals
3. Environmental decontamination
4. Management of secondary complications
5. Monitoring for zoonotic transmission

Systemic Acaricides

Isoxazolines: The isoxazoline class of ectoparasiticides has revolutionized the treatment of scabies in dogs. These compounds (fluralaner, afoxolaner, sarolaner, and lotilaner) are potent inhibitors of GABA-gated chloride channels in arthropods, providing rapid and sustained acaricidal activity.

• Fluralaner (Bravecto): Administered orally or topically, fluralaner provides 12 weeks of acaricidal activity. Multiple studies have demonstrated high efficacy (95-100%) for treatment of sarcoptic mange in dogs [2, 38]. A single oral dose is typically sufficient for cure, though a second dose at 12 weeks may be recommended in severe cases. Fluralaner has also been used successfully for treatment of sarcoptic mange in wildlife, including bare-nosed wombats [36].

• Afoxolaner (NexGard): Administered monthly, afoxolaner has shown excellent efficacy for treatment of scabies. A combination product containing afoxolaner, moxidectin, and pyrantel pamoate has been evaluated in field conditions and demonstrated high efficacy against naturally infested dogs [4]. Afoxolaner alone and in combination with milbemycin oxime has also been shown to be effective [40].

• Sarolaner (Simparica): Monthly administration of sarolaner, alone or in combination with moxidectin and pyrantel (Simparica Trio), provides effective treatment for sarcoptic mange. A randomized, double-blind study demonstrated high efficacy of the combination product for treatment of naturally acquired infestations [16].

• Lotilaner (Credelio): Monthly oral administration of lotilaner has been reported to be effective for treatment of sarcoptic mange, with clinical and parasitological cure achieved within 4-8 weeks [34].

A critically appraised topic comparing systemic treatments for sarcoptic mange concluded that isoxazolines represent the most effective systemic treatment option, with high efficacy, rapid onset of action, and excellent safety profiles [18].

Macrocyclic Lactones: Ivermectin and selamectin have been used historically for treatment of scabies in dogs.

• Ivermectin: Administered orally or subcutaneously at 200-400 mcg/kg, repeated at 2-week intervals for 2-3 treatments. Ivermectin is effective but requires multiple doses and is contraindicated in Collies and other herding breeds with MDR1 gene mutations.

• Selamectin (Revolution): Applied topically at monthly intervals. Selamectin has good efficacy for scabies but may require 2-3 monthly applications for complete resolution.

Moxidectin: Available in combination products (e.g., with imidacloprid as Advocate/Advantage Multi), moxidectin provides effective treatment for scabies with monthly application.

Topical Acaricides

Amitraz: Amitraz dips (250 ppm) applied weekly for 2-4 weeks are effective for treatment of scabies. However, amitraz is associated with significant side effects (sedation, bradycardia, hyperglycemia) and is less commonly used since the introduction of isoxazolines.

Lime Sulfur: Lime sulfur dips (2-3% solution) applied weekly for 4-6 weeks are effective and safe for use in puppies and pregnant dogs. The unpleasant odor and staining of fur limit owner compliance.

Permethrin: Permethrin-based products are available for topical application but are contraindicated in cats due to severe neurotoxicity.

Adjunctive Therapy

Antipruritic Therapy: The intense pruritus associated with scabies can be debilitating and may require symptomatic management during the initial phase of treatment. Oclacitinib (Apoquel), a Janus kinase inhibitor, has been shown to provide rapid relief of pruritus in dogs undergoing acaricidal treatment for scabies [37]. Short-term use of glucocorticoids (e.g., prednisolone at 0.5-1 mg/kg/day for 5-7 days) may also be considered for severe pruritus.

Antibiotic Therapy: Secondary pyoderma should be treated with appropriate antibiotics based on culture and sensitivity or empirical therapy with a first-generation cephalosporin (e.g., cephalexin at 22 mg/kg BID) or amoxicillin-clavulanate for 3-4 weeks.

Antiseborrheic Therapy: Keratolytic and keratoplastic shampoos (e.g., benzoyl peroxide, sulfur, salicylic acid) can help remove crusts and scales, improving skin condition and reducing mite burden.

Treatment of In-Contact Animals

All dogs and other in-contact animals (including cats, though they are less commonly affected) should be treated with an acaricidal agent, even if they are not showing clinical signs. Subclinically infested animals can serve as reservoirs for reinfestation.

Environmental Decontamination

Sarcoptes scabiei mites can survive off the host for 2-4 days under favorable conditions. Environmental decontamination involves:

• Washing bedding, collars, and grooming tools in hot water (60 degrees Celsius or higher) and drying on high heat
• Vacuuming carpets, upholstery, and kennel surfaces
• Treating kennels and crates with an acaricidal spray (e.g., permethrin-based products, following label instructions for use around pets)
• Disposing of contaminated materials that cannot be adequately cleaned

Monitoring and Follow-Up

Re-examination should be performed 2-4 weeks after initiation of treatment to assess response. Resolution of pruritus and skin lesions is expected within 2-4 weeks of effective acaricidal therapy. Repeat skin scrapings or dermoscopic examination can confirm parasitological cure.

In cases of treatment failure, consider:

• Inadequate dosing or administration
• Reinfestation from untreated in-contact animals or contaminated environment
• Resistance (rare but reported)
• Misdiagnosis (consider alternative diagnoses)

Zoonotic Considerations

Transmission to Humans

Scabies in dogs is a zoonotic disease. The mite Sarcoptes scabiei var. canis can transiently infest humans, causing a condition known as "canine scabies" or "pseudoscabies." Transmission occurs through direct contact with an infested dog or, less commonly, through contact with contaminated fomites.

Clinical Presentation in Humans

In humans, canine scabies typically presents as an intensely pruritic papular rash, often affecting the arms, trunk, and abdomen. The lesions are typically more widespread than those of human scabies (Sarcoptes scabiei var. hominis), but burrows are rarely seen. The pruritus is often severe and may be worse at night.

Course and Management

The mites cannot complete their life cycle on human skin and usually die within a few days. Therefore, the infestation is self-limiting, and symptoms typically resolve within 1-2 weeks after the source dog has been treated. Symptomatic treatment with antihistamines or topical corticosteroids may provide relief during this period.

However, in some cases, particularly with heavy or prolonged exposure, the infestation may persist longer. A global overview of zoonotic episodes of scabies documented numerous cases of transmission from dogs to humans, emphasizing the importance of recognizing this zoonotic potential [28].

Public Health Implications

The zoonotic nature of canine scabies has significant public health implications, particularly in regions with large stray dog populations and limited veterinary access. A study in northeast Brazil using a rapid assessment method covering an entire state documented the co-occurrence of human scabies and sarcoptic mange in dogs, highlighting the interconnectedness of human and animal health [9].

Recent research has also raised questions about potential links between canine scabies and rheumatic heart disease in humans. A call to reexamine this association has been published, suggesting that further epidemiological investigation is warranted [11].

One Health Approach

A One Health approach to scabies control recognizes the interconnectedness of human, animal, and environmental health. Effective control requires:

• Surveillance of scabies in domestic and wildlife populations
• Access to veterinary care for diagnosis and treatment
• Public education about zoonotic risks and prevention
• Collaboration between veterinary and human health professionals

Prevention and Control

Individual Animal Prevention

Prevention of scabies in individual dogs relies on:

• Regular Ectoparasite Control: Monthly administration of isoxazoline-based products (fluralaner, afoxolaner, sarolaner, lotilaner) provides continuous protection against S. scabiei infestation.
• Avoidance of High-Risk Environments: Limiting contact with stray dogs, wildlife, and potentially contaminated environments reduces exposure risk.
• Quarantine of New Animals: New dogs entering a household should be quarantined and treated with an acaricidal agent before introduction to resident animals.

Population-Level Control

Control of scabies in canine populations requires:

• Shelter and Kennel Management: Shelters and kennels should implement biosecurity protocols, including isolation of affected animals, routine cleaning and disinfection, and prophylactic treatment of high-risk animals.
• Stray Dog Management: Programs to reduce stray dog populations, including spay/neuter initiatives and responsible ownership education, can reduce disease prevalence.
• Wildlife Management: In areas where wildlife reservoirs are important, strategies to reduce contact between domestic dogs and wildlife should be implemented.

Wildlife Considerations

Scabies in wildlife populations is a significant conservation concern. Sarcoptic mange has caused devastating epidemics in endangered species, including the San Joaquin kit fox (Vulpes macrotis mutica) [39] and Andean foxes (Lycalopex culpaeus) [15]. The disease can cause high mortality rates and population declines.

A study of sarcoptic mange in two species of fox in human-dominated landscapes of central Chile documented the epizootiology and pathology of the disease, emphasizing the role of wildlife as reservoirs and the potential for spillover to domestic animals [14]. Similarly, pulmonary vascular proliferative lesions have been described in wild Korean raccoon dogs with sarcoptic mange, suggesting that the disease may have systemic effects beyond the skin [3].

Vaccine Development

Efforts to develop a vaccine against S. scabiei are ongoing. A new herbal medicine formulation with potential anti-scabies properties has been investigated for activity against Sarcoptes and Demodex parasites [12]. However, no commercial vaccine is currently available.

Special Considerations

Scabies in Cats

While this guide focuses on scabies in dogs, it is important to note that cats can also be affected by Sarcoptes scabiei. Feline sarcoptic mange is less common than in dogs but has been reported worldwide. A case series of three cats with sarcoptic mange in Poland described the clinical presentation and response to treatment [7].

The question of whether Sarcoptes scabiei var. felis exists as a distinct variant has been addressed by molecular studies. A first molecular study of sarcoptic mange in Felidae found that mites from cats are genetically similar to those from dogs, suggesting that cross-species transmission is possible [23].

Cats with scabies typically present with intense pruritus, crusting, and alopecia affecting the pinnae, face, and neck. Treatment with isoxazolines has been reported to be effective [17].

Scabies in Rabbits

Rabbits can be affected by sarcoptic and psoroptic mange. Isoxazolines have been evaluated for treatment of these conditions in rabbits and have shown good efficacy [17].

Drug Resistance

Resistance of S. scabiei to acaricidal agents is a growing concern. While resistance to isoxazolines has not been widely reported in dogs, it has been documented in other mite species. Rotating between different classes of acaricides may help delay the development of resistance.

Cost-Effectiveness of Treatment

The cost-effectiveness of different treatment options should be considered. Isoxazolines, while more expensive per dose than older treatments like ivermectin, offer the advantages of single-dose efficacy, reduced need for follow-up visits, and lower risk of treatment failure. The overall cost of treatment, including veterinary consultations, diagnostic tests, and management of complications, should be considered when selecting a treatment protocol.

Prognosis

The prognosis for scabies in dogs is excellent with appropriate treatment. Most dogs show significant improvement within 2-4 weeks of initiating acaricidal therapy, and complete resolution of clinical signs is expected within 6-8 weeks.

Factors associated with a favorable prognosis include:

• Early diagnosis and treatment
• Compliance with treatment protocols
• Treatment of all in-contact animals
• Adequate environmental decontamination
• Management of secondary complications

Factors associated with a guarded prognosis include:

• Severe, chronic infestations with extensive skin damage
• Concurrent immunosuppressive conditions
• Poor owner compliance
• Recurrent exposure from untreated in-contact animals or contaminated environment

Future Directions

Research into scabies in dogs continues to evolve. Key areas of ongoing investigation include:

• Improved Diagnostics: Development of rapid, point-of-care diagnostic tests for field use
• Vaccine Development: Identification of protective antigens for vaccine development
• Drug Resistance Monitoring: Surveillance for resistance to currently available acaricides
• One Health Approaches: Integration of human and animal health surveillance and control programs
• Wildlife Conservation: Development of strategies to mitigate the impact of scabies on endangered species

References

[1] Sánchez-Peralta VS, Moposa-Balarezo KL, Idrovo-Espín FM, et al. Cutaneous Larva Migrans Acquired in a Tropical Area of Ecuador: Diagnostic Delay, Clinical Evolution, and Recognition Challenges. Trop Med Infect Dis. 2026.

[2] Cruz BC, Teixeira MB, de Melo Cruz GA, et al. Efficacy of a fluralaner-based ectoparasiticide for the control of otodectic and sarcoptic mange in naturally infested dogs, evaluated in randomized, double-blind clinical studies. Parasit Vectors. 2026.

[3] Tangchang W, Song JY, Kim DH, et al. Pulmonary Vascular Proliferative Lesions in Wild Korean Raccoon Dogs (Nyctereutes procyonoides): Description of 13 Cases. Vet Sci. 2025.

[4] Antoine L, Papadopoulos E, Sioutas G, et al. Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei. Parasite. 2026.

[5] Colcuc M. Entodermoscopy to Diagnose Sarcoptic Mange: Visualising the Mite-Gallery Unit. Vet Dermatol. 2025.

[6] Astorga F, Ramírez-Álvarez D, Céspedes B, et al. Sarcoptic Mange in Wild Foxes (Lycalopex spp.) from Central Chile: Fine-Scale Assessment of a Global Disease. J Wildl Dis. 2025.

[7] Szczepanik M, Wilkolek P, Kalisz G, et al. Feline sarcoptic mange in Poland: A case series of three cats. Vet Med Sci. 2024.

[8] Wails CN, Helmke CC, Black KM, et al. Epidemiology of sarcoptic mange in a geographically constrained insular red fox population. Parasit Vectors. 2024.

[9] Silva NS, Alencar CH, Heukelbach J. Human scabies and sarcoptic mange in northeast Brazil: Results from a rapid assessment method covering an entire state. Trop Doct. 2024.

[10] Kaur G, Xie C, Dong C, et al. PDE4D and miR-203 are promising biomarkers for canine atopic dermatitis. Mol Biol Rep. 2024.

[11] Brookes VJ, Henning CE, Worthing KA, et al. Eliminate all risks: A call to reexamine the link between canine scabies and rheumatic heart disease. PLoS Negl Trop Dis. 2024.

[12] Hamed A, Amir R, Tahereh S, et al. A New Herbal Medicine Formulation with Potential Anti-scabies Properties to Treat Demodex and Sarcoptes Parasites. Arch Razi Inst. 2023.

[13] Saygın B, Girişgin AO, Zengin SA, et al. Distribution of Scabies Infestations in Stray Dogs in Bursa Province. Turkiye Parazitol Derg. 2024.

[14] Millán J, Cevidanes A, Di Cataldo S, et al. Epizootiology and Pathology of Sarcoptic Mange in Two Species of Fox (Lycalopex spp.) in Human-Dominated Landscapes of Central Chile. J Wildl Dis. 2024.

[15] Gomez-Puerta LA, Jara-Vila J, Anampa M, et al. Molecular characterization of Sarcoptes scabiei causing severe mange in two Andean foxes (Lycalopex culpaeus) from Peru. Parasitol Res. 2024.

[16] Becskei C, Liebenberg J, Fernandes T, et al. Efficacy of a chewable tablet containing sarolaner, moxidectin, and pyrantel (Simparica Trio) in the treatment of sarcoptic mange caused by Sarcoptes scabiei mite infestations in dogs. Parasit Vectors. 2023.

[17] Azaria H, Defalque VE. Isoxazolines for treating canine and feline otodectic mange; feline demodic